Webster Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Webster Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10	Closed	-$1K	–	570
2016 Q4	$1K	Buy	+10	New	+$860	﹤0.01%	580

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Webster Bank's BMRN Position: Q1 2017 in Review

Webster Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 10 shares — an estimated $1K sold.

Webster Bank first reported a position in BMRN in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Webster Bank reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Webster Bank sold 10 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $1K.
Webster Bank first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Webster Bank's BioMarin Pharmaceuticals position peaked at $1K in Q4 2016.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Webster Bank's 13F filing for Q1 2017, filed 1 May 2017.